We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

By LabMedica International staff writers
Posted on 01 Aug 2025

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. More...

Most diagnoses occur in later stages, when survival drops below 50% and treatment costs can soar. Over 10% of the U.S. population has an oral lesion, many of which may represent potentially malignant disorders that often go undetected or mischaracterized during routine dental visits. The lack of effective tools for early identification and monitoring of high-risk lesions in primary dental care creates a critical diagnostic gap. Now, a novel solution equips frontline dental providers with a faster, more accurate tool to detect and manage these lesions during routine care.

OraLiva (Durham, NC, USA\) has developed Onc In-Cyt, an artificial intelligence (AI)-powered “cytomics-on-a-chip” diagnostic platform for early detection and clinical management of oral potentially malignant disorders. This point-of-care platform uses minimally invasive brush biopsy samples and combines cytology with high-content imaging and deep learning to differentiate between benign and high-risk lesions. In earlier studies, the platform profiled over 13 million indexed cells from approximately 1,000 patients across a four-site international trial, revealing 128 novel cytological features that outperformed traditional markers in classifying oral epithelial dysplasia and squamous cell carcinoma.

The platform is currently offered as a laboratory-developed test (LDT) through OraLiva’s CLIA-certified lab. OraLiva is working on the design and assembly of stand-alone instrument units that integrate all platform features, along with finalizing specifications for future regulated point-of-care deployment. The company plans to accelerate development toward a regulated, commercially available point-of-care device, allowing frontline dental providers to detect and manage high-risk oral lesions during routine visits.

“By equipping frontline clinicians with smart, scalable tools, we aim to shift diagnosis earlier—when treatment is more effective, less invasive, and significantly less costly,” said Spencer Price, Chief Operating Officer at OraLiva.

Related Links:
OraLiva


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Blood Glucose Test Strip
AutoSense Test
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.